股价表现与目标价分析 - Kiniksa Pharmaceuticals International plc (KNSA) 近期股价表现强劲，过去四周上涨8.5%，最新收盘价为30.26美元 [1] - 华尔街分析师给出的平均目标价为41.14美元，意味着还有36%的上涨空间，最低目标价32美元(上涨5.8%)，最高目标价54美元(上涨78.5%) [1][2] - 分析师目标价的标准差为7.45美元，标准差越小表明分析师意见越一致 [2][9] 目标价的可信度分析 - 实证研究表明分析师目标价经常误导投资者，很少能准确预测股价走势 [7] - 华尔街分析师可能因商业利益关系而设定过于乐观的目标价，特别是对那些有业务往来的公司 [8] - 投资者不应完全依赖目标价做投资决策，应保持高度怀疑态度 [10] 盈利预测与评级 - 分析师近期普遍上调公司盈利预测，过去30天内当年共识EPS预期上调26.6%，且没有负面修正 [11][12] - 公司目前获得Zacks Rank 1(强力买入)评级，位列其覆盖的4000多只股票的前5% [13] - 盈利预测修正趋势与短期股价走势存在强相关性，这可能是更可靠的上涨信号 [11][14] 投资建议 - 虽然共识目标价本身可能不可靠，但它指示的价格方向仍具有参考价值 [14] - 分析师对盈利前景的乐观修正和高度一致的目标价区间可作为进一步研究公司基本面的起点 [4][9]

Zevra Therapeutics股票表现及分析师预测 - Zevra Therapeutics(ZVRA)股价在过去四周上涨16.8%至10.99美元 华尔街分析师给出的平均目标价23.86美元暗示仍有117.1%上行空间 [1] - 7位分析师目标价的标准差为3.39美元 最低目标价19美元(潜在涨幅72.9%) 最高目标价29美元(潜在涨幅163.9%) [2] - Zacks共识预期显示当前年度盈利预测过去30天增长337.1% 且无负面修正 [12] 分析师目标价的有效性分析 - 实证研究表明目标价常误导投资者 分析师对股价实际走向的判断准确率有限 [7] - 分析师可能因商业合作关系设定过度乐观目标价 但低标准差显示群体共识时参考价值提升 [8][9] - 目标价应保持审慎态度 不宜作为唯一投资决策依据 [10] 盈利预测修正的指示意义 - 分析师集体上调EPS预期的行为与短期股价走势存在强相关性 [11] - 公司当前获Zacks评级第二级(买入) 位列4000多只股票前20% 显示近期的上涨潜力 [13] - 盈利预测修正趋势比目标价更能可靠指示股价变动方向 [14] 投资参考框架 - 目标价离散度分析显示 低标准差(3.39美元)意味着分析师对上涨方向和幅度存在高度共识 [2][9] - 结合Zacks评级提升与盈利预测大幅上调 基本面支撑股价继续走强 [12][13] - 建议将目标价作为研究起点 而非绝对依据 需深入挖掘基本面驱动因素 [9][10]

Shares of uniQure (QURE) have gained 1.3% over the past four weeks to close the last trading session at $14.46, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.09 indicates a potential upside of 142.7%.The mean estimate comprises 11 short-term price targets with a standard deviation of $17.1. While the lowest estimate of $13.00 indicates a 10.1% decline from the current pric ...

West Pharmaceutical Services (WST) closed the last trading session at $252.94, gaining 13.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $316.82 indicates a 25.3% upside potential.The mean estimate comprises 11 short-term price targets with a standard deviation of $34.23. While the lowest estimate of $260.00 indicates a 2.8% increase from the current price level, the most optim ...

Shares of Montrose Environmental (MEG) have gained 2.1% over the past four weeks to close the last trading session at $22.39, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $29.4 indicates a potential upside of 31.3%.The mean estimate comprises five short-term price targets with a standard deviation of $4.83. While the lowest estimate of $24.00 indicates a 7.2% increase from th ...

Shares of Tango Therapeutics, Inc. (TNGX) have gained 18.7% over the past four weeks to close the last trading session at $6.46, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $10.43 indicates a potential upside of 61.5%.The mean estimate comprises seven short-term price targets with a standard deviation of $2.23. While the lowest estimate of $8.00 indicates a 23.8% increase fr ...

Kennedy-Wilson (KW) closed the last trading session at $7.6, gaining 9.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $9.9 indicates a 30.3% upside potential.The average comprises three short-term price targets ranging from a low of $7.70 to a high of $13.00, with a standard deviation of $2.76. While the lowest estimate indicates an increase of 1.3% from the current price level ...

股价表现与分析师目标价 - Revolution Medicines(RVMD)股价过去四周上涨2.7%至37.91美元 但华尔街分析师给出的短期平均目标价72.25美元意味着潜在90.6%上涨空间 [1] - 12位分析师目标价的标准差为7.86美元 最低目标价57美元(潜在涨幅50.4%) 最高目标价88美元(潜在涨幅132.1%) 标准差较小显示分析师共识度较高 [2] - 公司当前Zacks排名为2(买入) 位列4000多只股票前20% 近期年度共识EPS预估上调1% [12][13] 分析师目标价的可靠性分析 - 全球多所大学研究表明 分析师目标价误导投资者的频率高于指导作用 实证显示目标价很少能准确预测股价实际走向 [7] - 华尔街分析师可能因商业合作关系设定过度乐观目标价 但低标准差的目标价集群仍可作为研究基本面驱动力的起点 [8][9] - 投资者不应仅依赖目标价做决策 但目标价暗示的价格方向具有一定参考价值 [10][14] 盈利预期修正的积极信号 - 分析师对公司盈利前景日益乐观 EPS预估修正呈现强烈共识 这种趋势与短期股价走势存在强相关性 [4][11] - 过去30天内 当年Zacks共识EPS预估获1%上调 且无负面修正 显示盈利预期持续改善 [12]

股价表现与目标价分析 - Kimbell Royalty (KRP) 股价过去四周上涨4.4%至14.6美元，华尔街分析师平均目标价18.6美元隐含27.4%上行空间 [1] - 5个短期目标价区间为12-24美元，标准差4.98美元，最低目标价隐含17.8%跌幅，最高目标价隐含64.4%涨幅 [2] - 分析师目标价标准差反映预测分歧程度，标准差越小表明共识度越高 [2][9] 目标价的可信度问题 - 实证研究表明分析师目标价对股价预测准确性存疑，常误导投资者 [7] - 部分分析师因机构业务关系设定过度乐观目标价 [8] - 投资者不应仅依赖目标价做决策，需保持怀疑态度 [10] 盈利预测修正的积极信号 - 分析师一致上调EPS预测，当前年度Zacks共识预期30天内增长45.9% [4][12] - 盈利预测修正趋势与短期股价走势存在强相关性 [11] - KRP获Zacks Rank 2评级（前20%），显示近期的上涨潜力 [13] 综合评估框架 - 目标价方向性指引仍具参考价值，但需结合盈利修正等基本面因素 [14] - 低标准差目标价集群可作为研究公司基本面驱动力的起点 [9]

Shares of McEwen (MUX) have gained 18.3% over the past four weeks to close the last trading session at $11.5, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.99 indicates a potential upside of 30.4%.The average comprises four short-term price targets ranging from a low of $13.75 to a high of $15.70, with a standard deviation of $0.88. While the lowest estimate indicates an i ...